EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

Carina Dumo, Faheem iD, Peter J Choi, Nicholas J Pederson, Yuge Liu, Mike Dragunow, Thomas I-H Park, Katharine L Diehl, Jiney Jose iD

ChemMedChem · 2026-04-28 · 21 (8)

DOI: 10.1002/cmdc.70286 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-04-25. Written by Carina Dumo and 8 co-authors. Institution: Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand. Major MEDLINE topics: Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS, NIH HHS, Cure Kids.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain barrier (BBB). This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP‐ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB‐crossing heptamethine cyanine dye. We also present evidence for cellular uptake and PARP1 inhibition by the conjugate, which contributes to the observed improvement in potency.

Subjects

MeSH terms (MEDLINE)

PhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsCarbocyaninesGlioblastomaHumansPoly (ADP-Ribose) Polymerase-1Structure-Activity RelationshipCell Line, TumorPoly(ADP-ribose) PolymerasesDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugBrain Neoplasms

Author keywords

PARP inhibitionglioblastomaheptamethine cyanine dyesolaparib

Substances

olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Antineoplastic AgentsCarbocyaninesPARP1 protein, humanPoly(ADP-ribose) Polymerases

Authors and institutions

  • Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
  • Department of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
  • Neurosurgical Research Unit, The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
  • Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA.

ORCID profiles: Faheem, Jiney Jose

Funding

  • NIGMS NIH HHS
  • NIH HHS
  • Cure Kids
  • Neurological Foundation of New Zealand
  • Child Health Research Foundation
  • US National Institutes of Health

Cite

APA

Dumo, C., Faheem, Choi, P. J., Pederson, N. J., Liu, Y., Dragunow, M., Park, T. I., Diehl, K. L., & Jose, J. (2026). In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.70286

Vancouver

Dumo C, Faheem, Choi PJ, Pederson NJ, Liu Y, Dragunow M, et al. In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.70286

BibTeX
@article{Dumo2026,
  author = {Dumo, Carina and Faheem and Choi, Peter J and Pederson, Nicholas J and Liu, Yuge and Dragunow, Mike and Park, Thomas I-H and Diehl, Katharine L and Jose, Jiney},
  title = {In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {8},
  doi = {10.1002/cmdc.70286}
}
Start for free →